Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

NeOnc Technologies Inc
Profile last edited on: 5/18/23      CAGE: 6C243      UEI: TP8KS5F1YMM3

Business Identifier: Novel molecular technology providing enhanced targeted delivery of therapeutics for treatment of CNS-based diseases.
Year Founded
2008
First Award
2016
Latest Award
2020
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

8335 Sunset Boulevard Suite 240
West Hollywood, CA 90069
   (310) 663-7831
   info@neonctech.com
   www.neonctech.com
Location: Single
Congr. District: 43
County: Los Angeles

Public Profile

NeoOnc Technologies is a medical biotechnology company structured around development of novel delivery methods for pharma-based therapeutics targeting Brain and Central Nervous System (CNS) diseases. Management have developed a unique molecular wrapper technology that can effectively transport therapeutics directly to the brain without the normal boundary restrictions imposed by the body’s Blood-Brain Barrier (BBB). As a result, pharma companies that may have had limited success with their CNS therapeutics due to of current delivery restrictions will now be able to provide patients with far more effective treatments.

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$936,000
Phase II Dollars
$0
Total Awarded
$936,000

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
50-74

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2020 1 NIH $336,000
Project Title: Developing a Clinically Relevant Radiosensitizer for Temozolomide-Resistant Gliomas
2018 1 NIH $300,000
Project Title: Innovative Nose-To-Brain Anticancer Drug Transport Facilitated by NEO100
2016 1 NIH $300,000
Project Title: Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors

Key People / Management

  Thomas C Chen -- CEO and Chief CSO

  Alan Chiang

  Michael Davitz

  Eytan J Lombroso -- Vice Chairman Strategy And Business Developmen

  Vincent Simmon -- VP, Chief Regulatory Officer

  James F Walters -- Coo

  Patrick Walters -- Chief Financial Officer Corporate Secretary

Company News

May 13 2016
NeOnc Technologies Announces Initiation of Phase 1/2a Clinical Trial of NEO100™ in Recurrent Glioblastoma Multiforme (GBM)